Concinnity Genetics, an Edinburgh-based gene control company, has successfully closed its oversubscribed £3m seed funding round. The round was led by Eos Advisory and joined by Scottish Enterprise, Old College Capital (OCC) – the University of Edinburgh's in-house venture fund – and Maven Capital Partners.
Co-founded by Jessica Birt and Dr. Matthew Dale, Concinnity is advancing the safety of gene therapies by creating innovative control mechanisms using AI-powered platforms and synthetic biology. Its pioneering RNA-based systemsallow precise regulation of gene therapies after administration, enabling therapies to manage and minimize their own side effects effectively.
This investment will allow Concinnity to officially spin out from the UKRI UK Centre for Mammalian Synthetic Biology at the University of Edinburgh and establish a base in Scotland's vibrant life science sector. The funding will support the launch of three new programmes targeting critical areas in cell and gene therapy while advancing existing control systems to generate key data for partnerships.
CEO and Co-founder Jessica Birt said: “We are so excited to be taking the next step in our spin-out journey and want to sincerely thank all the investors and supporters who have helped us make it happen. Our ambition is to be the go-to partner for gene control to make gene and cell therapies as safe as possible.”
With strong backing and technology validation, Concinnity is positioned to make significant strides in gene therapy innovation, contributing to Scotland’s growing life sciences sector.
